Analisi di impatto sul budget sanitario italiano di enzalutamide per il trattamento del carcinoma prostatico metastatico ormono-sensibile

BACKGROUD: After demonstrating additional benefit versus standard of care in ARCHES and ENZAMET studies, enzalutamide was reimbursed in Italy in May 2022 by the National Health Service (NHS) for the treatment of hormone-sensitive metastatic prostate cancer (mHSPC). OBJECTIVE: This study estimates th...

Descripción completa

Detalles Bibliográficos
Autores principales: Fiorentino, Francesca, Di Rienzo, Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AboutScience 2023
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10105321/
https://www.ncbi.nlm.nih.gov/pubmed/37070066
http://dx.doi.org/10.33393/grhta.2023.2507

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10105321/
https://www.ncbi.nlm.nih.gov/pubmed/37070066
http://dx.doi.org/10.33393/grhta.2023.2507

Ejemplares similares